Lucky Core Industries Limited (LCI) has inaugurated a veterinary medicine manufacturing facility at its Sheikhupura site, marking an important development for Pakistan’s animal health sector. According to a notice submitted to the Pakistan Stock Exchange, the facility was formally inaugurated on March 30, 2026, and is located on the Lahore-Sheikhupura Road.

The company described the development as a key step in its strategic growth plans, stating that the new plant will strengthen its local manufacturing footprint and support veterinary business operations. The project is part of LCI’s ongoing expansion strategy in the Animal Health segment and reflects growing confidence in Pakistan’s livestock and poultry economy.

A Timely Boost for Pakistan’s Veterinary Industry

The establishment of this facility comes at a time when Pakistan’s veterinary, dairy, livestock, and poultry sectors require more reliable access to quality medicines and modern animal health solutions. By expanding local production, LCI is expected to improve the availability of veterinary pharmaceuticals for farmers, veterinarians, and industry stakeholders while also reducing dependence on imported products.

For a country where animal health directly affects farm productivity, food security, and rural livelihoods, such investments are being seen as strategically important. Increased local manufacturing can help strengthen disease management, improve supply continuity, and support better response to field-level treatment needs across Pakistan.

LCI’s Animal Health Portfolio and Manufacturing Capability

Lucky Core Industries Limited is a diversified public limited company operating across five key businesses: soda ash, polyester, chemicals & agri sciences, pharmaceuticals, and animal health. Within the animal health space, the company serves both livestock and poultry segments through a broad product range and manufacturing capability.

According to information available from the company’s business profile, LCI offers livestock solutions including anthelmintics, antiprotozoals, antibiotics, restoratives, hormonal products, nutritional formulations, bovine semen solutions, organic acids, feed additives, toxin binders, feed products, NSAIDs, and steroids. In poultry, the company also markets solutions such as antibiotic growth promoters, biologicals, nutritional products, disinfectants, organic acids, toxin binders, anticoccidials, antibiotics, and feed enzymes.

LCI states that it leverages best manufacturing practices to produce quality veterinary formulations at its Veterinary Medicine Plant. The company says these efforts are aimed at promoting better animal health and safeguarding overall well-being, thereby supporting farmers who rely on consistent and quality-backed solutions in the field.

Beyond medicines, the company also highlights its support for farm productivity through the Farmer’s Choice portfolio, under which it manufactures and markets its own cattle feed brand, LCI Vanda. The product is positioned as a solution to help fulfil the daily nutritional requirements of livestock while improving milk and meat yield.

This broader product and manufacturing framework suggests that the Sheikhupura facility is not an isolated expansion, but part of a larger business direction focused on integrated livestock and poultry support. For Pakistan’s veterinary and farming community, such moves may contribute to more organized and dependable access to treatment, nutrition, and production inputs.

Although the company reported a softer financial performance during the period, the inauguration of the new veterinary medicine facility signals a continued commitment to long-term growth in the animal health business. Industry observers are likely to view the investment as a forward-looking move aimed at capturing future demand in Pakistan’s evolving livestock and poultry markets.